Pharma Excipients

Sustained Release Agent

Injectable systems for long-lasting insulin therapy

Abstract Insulin therapy is the mainstay to treat diabetes characterizedd by hyperglycemia. However, its short half-life of only 4–6 min limits its effectiveness in treating chronic diabetes. Advances in recombinant DNA technology and protein engineering have led to several insulin analogue…
Read More...